MedTrace Logo

Diagnostic Study of Quantitative Imaging and Spectroscopy in Patients With Multiple Sclerosis

NCT00006060 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2009-03-12

No results posted yet for this study

Summary

OBJECTIVES: I. Determine by quantitative magnetic resonance imaging measurements the change in the total volume of brain parenchyma as well as its gray and white matter, T2 and enhanced T1 lesion volume, and the magnetization transfer ratio histogram parameters, and correlate these measurements with clinical measures of disability in patients with multiple sclerosis.

II. Measure the quantity of whole brain N-acetylaspartate in patients with multiple sclerosis and compare these values to those from age matched controls.

III. Determine the correlation between specific neuropsychological tests which assess global cognitive functioning and the quantitative measurements taken in these patients in this study.

Conditions

Interventions

DRUG

standard gadolinium contrast

Sponsors & Collaborators

Principal Investigators

  • Robert I. Grossman, MD · New York University

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1999-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00006060 on ClinicalTrials.gov